ReviewExpert review of vaccines2013
Dengue vaccines: recent developments, ongoing challenges and current candidates.
Review in Expert review of vaccines, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 101 citations in OpenAlex.
- Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.PLoS neglected tropical diseases · 2016Trial
- Heterogeneous co-circulation of multiple DENV-1 and DENV-2 genotypes in Vung Tau during the 2023 dengue outbreak in Vietnam.Tropical medicine and health · 2026Article
- High-Throughput Virtual Screening of Phytochemicals From Indian Medicinal Plants for the Identification of Potential Inhibitors Against NS2B-NS3 Protease of Dengue Virus.Biotechnology and applied biochemistry · 2026Article
- Development of attenuated and inactivated Dengue strains using advanced gene editing tools.Molecular biology reports · 2026Review
- Design of a novel epitope-based tetravalent subunit vaccine against dengue virus: An immunoinformatic approach.PloS one · 2026Article
- "Addressing rising dengue burden in Pakistan: is it time to consider dengue vaccination?"Annals of medicine and surgery (2012) · 2026Article
- Dengue Virus and the Host Immune System: A Battle of Immune Modulation, Response and Evasion.Pathogens (Basel, Switzerland) · 2025Review
- Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against Dengue.Vaccines · 2025Review
- Dengue fever in the Americas.Virulence · 2024Article
- Structure-based design of glycoprotein subunit vaccines for mumps.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Winged Threat on the Offensive: A Literature Review Due to the First Identification ofViruses · 2024Review
- Serological Cross-Reactivity in Zoonotic Flaviviral Infections of Medical Importance.Antibodies (Basel, Switzerland) · 2023Review
- Arthropod-Borne Flaviviruses in Pregnancy.Microorganisms · 2023Review
- Review
- Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022Review
- Host immunity and vaccine development against Dengue virus.Infectious medicine · 2022Review
- A comparative study of serological diagnosis of Dengue outbreak 2019.African health sciences · 2021Article
- Microbes increase thermal sensitivity in the mosquito Aedes aegypti, with the potential to change disease distributions.PLoS neglected tropical diseases · 2021Article
- Chemical characterization of billy goat weed extracts Ageratum conyzoides (Asteraceae) and their mosquitocidal activity against three blood-sucking pests and their non-toxicity against aquatic predators.Environmental science and pollution research international · 2021Article
- Production, Transmission, Pathogenesis, and Control of Dengue Virus: A Literature-Based Undivided Perspective.BioMed research international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Dengue is among the most prevalent and important arbovirus diseases of humans. To effectively control this rapidly spreading disease, control of the vector mosquito and a safe and efficacious vaccine are critical. Despite considerable efforts, the development of a successful vaccine has remained elusive. Multiple factors have complicated the creation of a successful vaccine, not the least of which are the complex, immune-mediated responses against four antigenically distinct serotypes necessitating a tetravalent vaccine providing long-lasting protective immunity. Despite the multiple impediments, there are currently many promising vaccine candidates in preclinical and clinical development. Here, the recent advances in dengue virus vaccine development are reviewed and the challenges associated with the use of these vaccines as a public health tool are briefly discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.